Fexofenadine in Patients With Active Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the
world population, resulting in the loss of joint function and progressive structural damage
in affected joints. Fexofenadine has been widely used to treat various allergic diseases,
like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular
mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling